The Platform Optimizing SynBio for Early Intervention and Detection in Oncology (POSEIDON) program, developed by ARPA-H, seeks proposals to revolutionize cancer screening by creating at-home, over-the-counter Multi-Cancer Early Detection (MCED) tests. 

These tests will detect 30+ cancers at Stage 1 using breath or urine samples, to save lives and reduce the economic burden of late-stage cancer care. Eligible applicants include businesses, academic researchers, non-profit organizations, and more. 

Submit your solution summary by November 6th, 2024. To learn more about the program, visit the POSEIDON ARPA-H information webpage.